Renal transplantation at the University of Pittsburgh: the impact of XXXX .

@entity1 @entity229 @entity2132 @entity1140 @entity230 @entity2359
1. In an unselected adult renal transplant population, @entity1140 as the primary immunosuppressive agent yielded one- and 2-year actuarial @entity1 survival rates of 95% and 93% and one- and 2-year actuarial graft survival rates of 89% and 83%, respectively. Forty-nine percent of successfully transplanted @entity1 were weaned off @entity230 . 2. In pediatric renal transplant @entity1 , @entity1140 has been associated with 100% one- and 3-year actuarial @entity1 survival rates and 98% and 85% one- and 3-year actuarial graft survival rates, respectively. Sixty-two percent of successfully transplanted @entity1 were taken off @entity229 , with dramatic improvements in height. 3. @entity1140 has been used successfully in rescuing 70-74% of adult or pediatric renal transplant @entity1 with an acute rejection that failed conventional therapy. 4. Kidney/bone marrow transplantation under @entity1140 therapy has been successfully performed without @entity2132 and with routine augmentation of chimerism. 5. The side effects of @entity1140 included nephrotoxicity, @entity2359 , and diabetogenicity; they were comparable to those seen with CsA. 6. @entity1140 is an important new addition to the immunosuppressive armamentarium in renal transplant @entity1 .
